Trial Profile
A single-center, single-arm, observational study to evaluate the tolerability and efficacy of carfilzomib-based therapy for antibody mediated rejection in adult patients with lung transplant recipients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Lung transplant rejection
- Focus Adverse reactions
- 08 Apr 2017 Results (n=19) presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
- 07 Feb 2017 Results (n=14) assessing effect of carfilzomib on antibody mediated rejection of the pulmonary allografts, published in the American Journal of Transplantation
- 30 Apr 2016 Results (n=16) assessing the impact of pre-treatment donor specific HLA antibody titer on the carfilzomib-based therapy efficacy presented at the 36th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.